

**FEDERAL RESERVE SYSTEM****Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company**

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Federal Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than December 5, 2019.

*A. Federal Reserve Bank of San Francisco* (Gerald C. Tsai, Director, Applications and Enforcement) 101 Market Street, San Francisco, California 94105-1579:

1. *John G. Sorensen, Jr., president of JGS, Jr. Family Holding Corporation, individually, and together with Sondra S. Swindle, president of SSS Family Holding Corporation, all of Salt Lake City, Utah;* to be approved as members of a group acting in concert to retain voting shares of Home Credit Corporation, and thereby indirectly retain voting shares of Home Savings Bank, both of Salt Lake City, Utah.

Board of Governors of the Federal Reserve System, November 18, 2019.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2019-25250 Filed 11-20-19; 8:45 am]

**BILLING CODE 6210-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Medicare & Medicaid Services**

[Document Identifier CMS-10718]

**Agency Information Collection Activities: Proposed Collection; Comment Request; Correction**

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), HHS.

**ACTION:** Correction of notice.

**SUMMARY:** This document corrects the information provided for [Document Identifier: CMS-10718] titled "Model Medicare Advantage and Medicare Prescription Drug Plan Individual Enrollment Request Form."

**FOR FURTHER INFORMATION CONTACT:** William N. Parham, III, (410) 786-4669.

**SUPPLEMENTARY INFORMATION:****I. Background**

In the November 18, 2019, issue of the **Federal Register** (84 FR 63655), we published a Paperwork Reduction Act notice requesting a 60-day public comment period for the information collection request identified under CMS-10718, OMB control number 0938-New, and titled "Model Medicare Advantage and Medicare Prescription Drug Plan Individual Enrollment Request Form."

**II. Explanation of Error**

In the November 18, 2019, notice, the information provided in the first column of the first paragraph, on page 63657, was published with incorrect information in the "Total Annual Hours" section. This notice corrects the language found in the "Total Annual Hours" section in the first column of the first paragraph, on page 63657 the November 18th notice. All of the other information contained in the November 18, 2019, notice is correct. The related public comment period remains in effect and ends January 17, 2020.

**III. Correction of Error**

In FR Doc. 2019-24930 of November 18, 2019 (84 FR 63655), page 63657, the language in the first column, first paragraph of the notice that begins with "Total Annual Hours: 10,324,481" and ends with "(For policy questions regarding this collection contact Deme Umo at (410) 786-8854.)" is corrected to read as follows:

*Total Annual Hours: 7,861,354.* (For policy questions regarding this collection contact Deme Umo at (410) 786-8854.)

Dated: November 18, 2019.

**William N. Parham, III,**

*Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.*

[FR Doc. 2019-25283 Filed 11-20-19; 8:45 am]

**BILLING CODE 4120-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA-2019-D-4447]

**Transdermal and Topical Delivery Systems—Product Development and Quality Considerations; Draft Guidance for Industry; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Transdermal and Topical Delivery Systems—Product Development and Quality Considerations." This guidance provides recommendations to applicants and manufacturers of transdermal and topical delivery systems (TDS) regarding the pharmaceutical development and quality information to include in new drug applications (NDAs) and abbreviated new drug applications (ANDAs). Specifically, the guidance discusses FDA's current thinking on product design and pharmaceutical development, manufacturing process and control, and finished product control. It also addresses special considerations for areas where quality is closely tied to product performance and potential safety issues, such as adhesion failure and the impact of applied heat on drug delivery.

**DATES:** Submit either electronic or written comments on the draft guidance by February 19, 2020 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

**ADDRESSES:** You may submit comments on any guidance at any time as follows:

**Electronic Submissions**

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your